Actinium Pharma and Astellas Move to Third Phase of Their Collaboration

The partnership involves the use of Actinium’s Antibody Warhead Enabling tech for conjugation and labeling of targeting agents from Astellas.

 A research collaboration established in early 2018 between Actinium Pharmaceuticals and Astellas Pharma continues to progress. As part of the deal, Actinium is responsible for developing Actinium-225 Radio-Conjugates (ARCs) of selected Astellas targeting agents using its Actinium Warhead Enabling (AWE) platform technology and conducting preclinical studies of the generated ARCs. In return, Actinium has received up-front payment and research funding from Astellas.

 

Recently, the two companies announced that Actinium successfully completed the second module of the research and option agreement with Astellas and initiated the third and final module.

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.